1. Poland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Biomaxima SA

Biomaxima SA

GGPW:BMX
9.85
PLN
-0.05
(-0.51%)
0.24EPS
45.94P/E
47.17MMarket Cap
Dec 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.9
6.72
7.23
7.37
8.47
8.26
8.17
14.84
18.31
33.25
10.84
12.6
14.52
14.68
Basic EPS, GAAP
0.43
0.15
0.48
0.29
0.22
-0.13
- -
1.93
2.37
6.68
0.14
0.13
0.03
0.24
Free Cash Flow per Basic Share
0.09
0.14
0.7
0.27
-0.09
-4.1
0.88
0.64
-0.03
8.57
0.37
-0.04
0.8
0.17
Dividend per Share
- -
- -
0.1
0.26
0.1
- -
- -
- -
0.25
0.45
0.49
- -
- -
- -
Book Value per Share
4.73
4.77
5.14
4.48
4.64
4.49
4.4
4.6
6.76
12.65
11.2
11.29
11.47
11.44
Tangible Book Value per Share
3.66
4.05
4.62
3.9
4.27
4.16
4
4.47
6.64
12.54
11.11
11.21
11.33
11.22
Basic Weighted Avg Shares
3
3
3
4
4
4
4
4
4
4
4
4
4
4
Sales/Revenue/Turnover
21
20
22
27
32
31
30
61
79
144
47
53
61
62
Operating Margin (%)
8.07
190.47
7.96
5.18
3.43
0.16
2.54
15.98
16.57
24.12
-0.51
2.1
1.58
1.31
Depreciation Expense
2
2
2
2
2
1
2
1
2
2
2
3
4
4
Net Income, GAAP
1
- -
1
1
1
- -
- -
8
10
29
1
1
- -
1
Effective Tax Rate (%)
15.59
- -
13.7
13.46
9.53
- -
92.29
16.9
19.82
19.47
- -
- -
44.15
18.1
Profit Margin (%)
6.3
2.23
6.62
3.9
2.55
-1.56
-0.04
12.97
12.95
20.08
1.25
1.01
0.17
1.67
Working Capital
8
7
11
9
9
2
6
12
16
25
12
8
11
8
LT Debt
4
2
4
1
2
7
6
8
9
4
9
6
8
5
Total Equity
14
14
16
17
17
17
16
20
29
52
47
47
48
48
Return on Invested Capital (%)
7.22
- -
7.65
5.48
4.34
- -
0.17
28.16
27.5
53.23
- -
- -
1.11
2.9
Return on Capital (%)
7.71
- -
8.03
6.78
5.07
- -
-0.02
27.03
26.41
55.88
- -
- -
1.23
3
Return on Common Equity (%)
9.16
3.15
9.66
6.64
4.74
-2.83
-0.08
43.79
41.74
70.75
1.18
1.13
0.22
2.17

Capital Structure

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
11
6
11
LT Borrowings
4
6
4
LT Finance Leases
1
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
60
51
47

Working Capital

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
27
26
28
Cash, Cash Equivalents & STI
1
2
- -
Accounts Receivable, Net
9
7
9
Inventories
14
14
15
Total Current Liabilities
19
15
20
Payables & Accruals
- -
- -
- -
ST Debt
11
6
11
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.47%
23.68%
1.59%
Free Cash Flow
-2,656.82%
-6,161.91%
-2,319.74%
Net Income, GAAP
-5,923.74%
4.76%
-80.37%
Sales/Revenue/Turnover
20.92%
14.34%
15.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
12
13
16
53
2025
15
- -
15
18
61
2026
14
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
-0.1
-0.06
0.23
0.13
2025
0.14
- -
-0.07
0.1
0.03
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Lukasz Maria Urban
Full Time Employees
143
Sector
Health technology
Industry
Medical specialties
Address
ul. Vetterów 5 Lublin LU Poland 20-277
IPO Date
Jun 8, 2010
Website
biomaxima.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics, serving clinical, veterinary, and industrial laboratories primarily in Poland and through exports to over 65 markets on four continents; its core products encompass analyzers and diagnostic reagents for clinical chemistry testing of blood and body fluids, antibiotic susceptibility testing systems, rapid diagnostic tests with readers for infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, immunological analyzers for cardiac markers, professional glucometers, gasometric analyzers for critical blood parameters, chromogenic dehydrated and prepared culture media, antibiotics discs and MIC strips, media additives and supplements, microbank storage systems, surfaces and air controls, molecular biology products including sample inactivation and transport media, veterinary products, and devices for microbiological analysis, complemented by training activities. Founded in 1997 and headquartered in Lublin, Poland, the company, listed on the Warsaw Stock Exchange, holds ISO 9001:2015, ISO 13485:2016, and ISO 17025:2018-02 certifications, with CE-marked products compliant with EU IVDR 2017/746, and distributes offerings from global partners such as Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe, and Biolog while supplying approximately 1,800 to 2,000 laboratories in Poland. Recent developments include acquisition of 100% shares in Polab Sp. z o.o. in Plock alongside its NewConnect debut, permission to operate in the EURO-PARK MIELEC Lublin Special Economic Zone subzone from the Industrial Development Agency, winning tender procedures in Poland during 2024, and sustained export growth with microbiology sales rising to 30.74 million PLN and total Polish revenues reaching 34.24 million PLN in fiscal year 2024.